Should HEXO (TSX:HEXO) Stock Be on Your Contrarian Buy List?

Is HEXO (TSX:HEXO) now oversold?

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Marijuana stocks took a big hit in the second half of 2019 and the cannabis sector continues to struggle as we begin 2020.

HEXO (TSX:HEXO)(NYSE:HEXO) has really taken a hit, falling from $11 per share last April to a below $2. At the time of writing HEXO trades at $1.80 and has a market capitalization of about $450 million.

Let’s take a look the reasons for the rout and try to determine whether HEXO deserves to be a contrarian buy for your portfolio today.

Industry woes

Investors piled into pot stocks ahead of the launch of the recreational market in October 2018 with high hopes for the industry. The initial rollout didn’t go as planned, with supply shortages and distribution challenges hampering sales and frustrating potential customers.

The sector caught a second wind, however, in the first four months of 2019. The rebound in the share prices of the cannabis companies came as part of an overall recovery in equity markets.

Renewed enthusiasm about sales for the year also helped bring investors back into the sector, and some had an eye on getting in ahead of the launch of the second phase of Canada’s recreational pot legalization.

Unfortunately, the quarterly reports coming from the cannabis producers started to indicate that challenges remained. Revenue growth began to stall out, while expenses and losses moved steadily higher. This made investors question their appetite for holding stocks with such lofty valuations.

In addition, the industry started to lose credibility as reports emerged that some companies were not following the rules. Production in non-licensed facilities and accusations of self-dealing by some industry executives gave investors and lenders another reason to take a step back.

HEXO’s issues

HEXO’s trouble began with its acquisition of Newstrike Brands in the first part of 2019. The deal was initially viewed as positive for HEXO as it expanded the company’s licensing reach to eight provinces and added important production capacity and new brands to the portfolio.

At the time of the deal, HEXO said fiscal 2020 revenue could hit $400 million. In June, the company maintained the optimistic guidance, even saying that it expected its fiscal Q4 2019 revenue, which covered the three months that ended July 31, to be close to $26 million, or about double the previous quarter.

In October, the management team stepped back the guidance and painted a very different outlook for the 2020 fiscal year. HEXO cut 200 jobs and shut down a former Newstrike production site. When the fiscal Q4 2019 results actually came out, net revenue was just $15.4 million.

The fiscal Q1 2020 report, showed net revenue of $14.5 million and a net loss of $62.4 million. On an annualized basis projected fiscal 2020 revenue at the same rate would be less than $60 million, well off the $400 million the company anticipated just six months ago.

HEXO recently raised US$25 million through a share issue at US$1.67 per share. This followed a $70 million loan provided to the company by a group that primarily consisted of HEXO executives and board members.

Should you buy HEXO?

Given the ongoing high level of cash burn, investors should be careful. Revenue would have to pick up considerably to get the company to profitability and enable HEXO to start to attract new investors.

The recent launch of the edibles and drinks market could provide the revenue surge HEXO needs, but the early indication is that the market is adopting a wait-and-see approach.

The stock could certainly rally on reports of better-than-expected revenue in the coming quarters. Any rumours of a takeover could also drive the share price higher.

At this point, however, I would probably search for other opportunities.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. Fool contributor Andrew Walker has no position in any stock mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »